Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Regulatory & Policy
Tracking regulations, policy shifts, and government decisions. Coverage of CDSCO, NPPA, pricing controls, and compliance updates. Explaining policy impact on industry and markets.
1
2
3
